Cargando…

Correction to: Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1

Detalles Bibliográficos
Autores principales:	Okła, Karolina, Rajtak, Alicja, Czerwonka, Arkadiusz, Bobiński, Marcin, Wawruszak, Anna, Tarkowski, Rafał, Bednarek, Wiesława, Szumiło, Justyna, Kotarski, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315484/ https://www.ncbi.nlm.nih.gov/pubmed/32586330 http://dx.doi.org/10.1186/s12967-020-02431-8

Ejemplares similares

Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1
por: Okła, Karolina, et al.
Publicado: (2020)

Clinical Relevance and Immunosuppressive Pattern of Circulating and Infiltrating Subsets of Myeloid-Derived Suppressor Cells (MDSCs) in Epithelial Ovarian Cancer
por: Okła, Karolina, et al.
Publicado: (2019)

Clinical Relevance of Mortalin in Ovarian Cancer Patients
por: Rajtak, Alicja, et al.
Publicado: (2023)

Isobolographic Analysis Demonstrates the Additive and Synergistic Effects of Gemcitabine Combined with Fucoidan in Uterine Sarcomas and Carcinosarcoma Cells
por: Bobiński, Marcin, et al.
Publicado: (2019)

Gemcitabine and Selected mTOR Inhibitors in Uterine Sarcomas and Carcinosarcoma Cells- an Isobolographic Analysis
por: Bobiński, Marcin, et al.
Publicado: (2020)

Integration of local and systemic immunity in ovarian cancer: Implications for immunotherapy
por: Rajtak, Alicja, et al.
Publicado: (2022)

Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients
por: Pawłowska, Anna, et al.
Publicado: (2021)

Microvessels Density in Uterine Leiomyosarcoma
por: Bobiński, Marcin, et al.
Publicado: (2015)

PD-L1/miR-155 Interplay in Pediatric High-Grade Glioma
por: Litak, Jakub, et al.
Publicado: (2022)

The Effect of Fucoidan, a Potential New, Natural, Anti-Neoplastic Agent on Uterine Sarcomas and Carcinosarcoma Cell Lines: ENITEC Collaborative Study
por: Bobiński, Marcin, et al.
Publicado: (2019)

PD-L1 Expression Correlated with p53 Expression in Pediatric Glioblastoma Multiforme
por: Litak, Jakub, et al.
Publicado: (2021)

Clinical Value of the PD-1/PD-L1/PD-L2 Pathway in Patients Suffering from Endometriosis
por: Suszczyk, Dorota, et al.
Publicado: (2022)

Programmed Death-1 Receptor (PD-1) as a Potential Prognosis Biomarker for Ovarian Cancer Patients
por: Pawłowska, Anna, et al.
Publicado: (2020)

PD-L1(+)MDSCs are increased in HCC patients and induced by soluble factor in the tumor microenvironment
por: Iwata, Tomoaki, et al.
Publicado: (2016)

Influence of ovarian cancer type I and type II microenvironment on the phenotype and function of monocyte-derived dendritic cells
por: Surówka, J., et al.
Publicado: (2017)

Preoperative Differentiation of Uterine Leiomyomas and Leiomyosarcomas: Current Possibilities and Future Directions
por: Żak, Klaudia, et al.
Publicado: (2022)

The Increase of Circulating PD-1- and PD-L1-Expressing Lymphocytes in Endometriosis: Correlation with Clinical and Laboratory Parameters
por: Walankiewicz, Monika, et al.
Publicado: (2018)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Myeloid-derived suppressor cells (MDSCs): what do we currently know about the effect they have against anti-PD-1/PD-L1 therapies?
por: Tellez, Ronald Sergio Limón, et al.
Publicado: (2023)

PD-1/PD-L1 and DNA Damage Response in Cancer
por: Kciuk, Mateusz, et al.
Publicado: (2023)

Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
por: Skalniak, Lukasz, et al.
Publicado: (2017)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

Efficacy of PD-1/PD-L1 inhibitors against pretreated advanced cancer: a systematic review and meta-analysis
por: Hu, Hao, et al.
Publicado: (2018)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

The Role of BCL-2 and PD-1/PD-L1 Pathway in Pathogenesis of Myelodysplastic Syndromes
por: Kuszczak, Bartłomiej, et al.
Publicado: (2023)

Prognostic and Clinical Value of Interleukin 6 and CD45(+)CD14(+) Inflammatory Cells with PD-L1(+)/PD-L2(+) Expression in Patients with Different Manifestation of Ovarian Cancer
por: Wertel, Iwona, et al.
Publicado: (2020)

Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
por: Shen, Xian, et al.
Publicado: (2018)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
por: Niu, Mengke, et al.
Publicado: (2022)

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
por: Zhao, Xuan, et al.
Publicado: (2022)

PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance
por: Huang, Changsheng, et al.
Publicado: (2023)

High‐affinity PD‐1 molecules deliver improved interaction with PD‐L1 and PD‐L2
por: Li, Yanyan, et al.
Publicado: (2018)

Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer
por: Jeong, Seri, et al.
Publicado: (2021)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

PD-L1/PD-1 Axis in Glioblastoma Multiforme
por: Litak, Jakub, et al.
Publicado: (2019)

A snapshot of the PD-1/PD-L1 pathway
por: Ghosh, Chinmoy, et al.
Publicado: (2021)

The PD-1:PD-L1 axis in Inflammatory Arthritis
por: Canavan, Mary, et al.
Publicado: (2021)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

PD-1/PD-L1 axis in organ fibrosis
por: Zhao, Youliang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hqkt5cbqm2rgmchuhh6f4dugnk